EUVIMEDEUVIMED entdecken
Crossref

ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study

Dongsheng Xu, You Zhang, Wei Huang, Xinbing Pan, Shuxian An, Cheng Wang, Gang Huang, Jianjun Liu, Weijun Wei iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06910-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Dongsheng Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, …. Hauptthemen laut MEDLINE: Epithelial Cell Adhesion Molecule, Single-Domain Antibodies, Positron-Emission Tomography, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shen Kang-United Imaging Joint Research and Development Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Epithelial cell adhesion molecule (EpCAM) is a potential therapeutic target and anchoring molecule for circulating and disseminated tumour cells (CTC/DTC) in liquid biopsy. In this study, we aimed to construct EpCAM-specific immuno-positron emission tomography (immunoPET) imaging probes and assess the diagnostic abilities in preclinical cancer models. METHODS: By engineering six single-domain antibodies (e.g., EPCD1 - 6) targeting EpCAM of different binding properties and labelling with 68Ga (T1/2 = 1.1 h) and 18F (T1/2 = 110 min), we developed a series of EpCAM-targeted immunoPET imaging probes. The probes' pharmacokinetics and diagnostic accuracies were investigated in cell-derived human colorectal (LS174T) and esophageal cancer (OE19) tumour models. RESULTS: Based on in vitro binding affinities and in vivo pharmacokinetics of the first three tracers ([68Ga]Ga-NOTA-EPCD1, [68Ga]Ga-NOTA-EPCD2, and [68Ga]Ga-NOTA-EPCD3), we selected [68Ga]Ga-NOTA-EPCD3 for tumour imaging which showed an average tumour uptake of 2.06 ± 0.124%ID/g (n = 3) in LS174T cell-derived tumour model. Development and characterisation of [18F]AIF-RESCA-EPCD3 showed comparable tumour uptake of 1.73 ± 0.0471%ID/g (n = 3) in the same tumour model. Further validation of [68Ga]Ga-NOTA-EPCD3 in OE19 cell-derived tumour model showed an average tumour uptake of 4.27 ± 1.16%ID/g and liver uptake of 13.5 ± 1.30%ID/g (n = 3). Near-infrared fluorescence imaging with Cy7-EPCD3 confirmed the in vivo pharmacokinetics and relatively high liver accumulation. We further synthesized another three 18F-labeled nanobody tracers ([18F]AIF-RESCA-EPCD4, [18F]AIF-RESCA-EPCD5, and [18F]AIF-RESCA-EPCD6) and found that [18F]AIF-RESCA-EPCD6 had the best pharmacokinetics with low background. [18F]AIF-RESCA-EPCD6 showed explicit uptake in the subcutaneously inoculated OE19 tumour model with an average uptake of 4.70 ± 0.26%ID/g (n = 3). In comparison, the corresponding tumour uptake (0.17 ± 0.25%ID/g, n = 3) in the EPCD6 blocking group was substantially lower (P < 0.001), indicating the targeting specificity of the tracer. CONCLUSIONS: We developed a series of 68Ga/18F-labeled nanobody tracers targeting human EpCAM. ImmunoPET imaging with [18F]AIF-RESCA-EPCD6 may facilitate better use of EpCAM-targeted therapeutics by noninvasively displaying the target's expression dynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial Cell Adhesion MoleculeSingle-Domain AntibodiesPositron-Emission TomographyNeoplasmsHumansAnimalsCell Line, TumorMiceRadioactive TracersGallium RadioisotopesTissue Distribution

Stichwörter der Autor:innen

EpCAMImmunoPETMolecular imagingSingle-domain antiboy

Substanzen

Epithelial Cell Adhesion MoleculeSingle-Domain AntibodiesRadioactive TracersGallium RadioisotopesEPCAM protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
  • Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. ljjsh@sjtu.edu.cn.
  • Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. wwei@shsmu.edu.cn.

ORCID-Profile: Weijun Wei

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shen Kang-United Imaging Joint Research and Development Plan

Zitieren

APA

Xu, D., Zhang, Y., Huang, W., Pan, X., An, S., Wang, C., Huang, G., Liu, J., & Wei, W. (2025). ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06910-8

Vancouver

Xu D, Zhang Y, Huang W, Pan X, An S, Wang C, et al. ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06910-8

BibTeX
@article{Xu2025,
  author = {Xu, Dongsheng and Zhang, You and Huang, Wei and Pan, Xinbing and An, Shuxian and Wang, Cheng and Huang, Gang and Liu, Jianjun and Wei, Weijun},
  title = {ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06910-8}
}
Kostenlos starten →